|
|
Advancing the Care of Patients Living with EGPA Through Multidisciplinary, Patient-Focused Care
Target Audience
This educational activity is intended for rheumatologists, allergists, immunologists, pulmonologists, and specialty advance practice clinicians who care for patients with EGPA.
Program Overview
The comprehensive program provides up-to-date information regarding EGPA"its recognition, diagnosis, and treatment"and incorporates the patient perspective to raise awareness of patients’ needs, heighten urgency, and, ultimately, educate on the disease. The program will ... |
|
|
Hot Topics in Lupus: SLE Pathophysiology
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Individualizing Steroid-Sparing Regimens
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Targeted Biologic Treatment Options
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Rheumatology 101 for the Primary Care Clinician
The Pacific Northwest is experiencing a critical shortage of rheumatologists. Despite efforts from multiple organizations, including the American College of Rheumatology, The Arthritis Foundation, The University of Washington, and Virginia Mason Medical Center, Washington State continues to rank near the bottom for access issues. In a May 2022 interview, Washington Rheumatology Alliance (WRA) President Jeff Peterson, MD noted with concern that rural patients are particularly underserved, with ... |
|
|
FOP: Enhancing Diagnosis and Management to Improve Patients’ Quality of Life
Target Audience
The educational design of this activity addresses the needs of the primary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, and genetic counselors, and the secondary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, and specialist NPs and PAs.
Program Overview
Because fibrodysplasia ossificans progressiva, or FOP, is exceedingly rare, even specialists... |
|
|
Dialogues about FOP: What Patients Wish More Doctors Knew to Enhance Early Recognition and Management
Target Audience
The educational design of this activity addresses the needs of the primary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, and the secondary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists.
Statement of Need/Program Overview
Fibrodysplasia ossificans progressiva (FOP) causes abnormal bone for... |
|
|
Highlights of the 2023 EULAR Guideline Updates in SLE- What you need to know!
This educational program will review the latest updates to the European Alliance of Associations for Rheumatology (EULAR) guidelines for the treatment of SLE and lupus nephritis (LN). Dr. Eric Morand highlights the most important changes to the guidelines and gives key insights into actionable changes that impact individualized patient care. |
|